OPHTHALMIC DRUG DELIVERY

Document Sample
OPHTHALMIC DRUG DELIVERY Powered By Docstoc
					OPHTHALMIC DRUG DELIVERY
1. Key concept on ophthalmic drug delivery
       a. Route of absorption - ONLY through anterior segment tissue (cornea to lense)
       b. Amount of absorption - < 1% of instilled dose = poor bioavailability → 99% get into systemic circulation → high
          enough concentration → systemic side effects
2. Disease of the eye
       a. Anterior segment ocular disorder
                 i. Dry eye – could be due to many different disorder (autoimmune, etc)
                ii. Infection – found in other countries & babies due to lack of immune system in eye
              iii. Glaucoma – increase in ocular pressure → optic nerve damage → diagnosis by measuring optic pressure
               iv. Cataracts – lens disorder, no drug available → surgery
       b. Posterior segment ocular disorder → must inject drug into the back of eye to treat
                 i. Degeneration – age related macular degeneration (ARMD), retinitis pigmentosa
                ii. Vascular – diabetic retinopathy, retinal vein/artery occlusion, retinopathy of prematurity
              iii. Inflammation – uveitis
               iv. Infection – endophthalmitis
                v. Other – glaucoma, optic neuritis
3. Anatomy of eye




       a. Schlemm’s canal – drain aqueous humor from eye → no
          build up of pressure → no optic nerve damage
       b. Vitreous chamber – filled with gello-like hydroacid fluid
       c. Ciliary body – secrete NaCl into anterior chamber →
          water follow into anterior chamber
                i. Glaucoma drug - ↓ inflow & ↑ outflow → ↓
                   pressure
       d. Iris – had pigment produced by melanocyte → non-
          covalently bind to drug → keep drug around longer →
          good/bad depending what kind of drug & what drug is for
       e. Conjunctiva – highly vascularized, transparent layer that
          coat 80% of eye surface, sitting on top of sclera layer,
          continuous with cornea → major route for drug to enter
          systemic circulation
                i. Has globet cell → produce major component of tear (mucin, glycoprotein & antioxidant) → may interfere
                   with drug delivery
               ii. Mechanism of transport – Paracellular – for hydrophilic solute (ions & water) → allow molecules up to
                   20kDa through (equivalent to pore wit radius of 5.5nm) >< < 5kDa for cornea
                       1. Active transporter on conjunctiva – L-NAME, neutral & cationic aa, nucleoside analog
              iii. Has microvilli cell – directional transport substance in 1 direction
       f. Aqueous humor
                i. Composition – 0.02% protein, with 1%/min turn-over rate
               ii. Location
                       1. Anterior chamber – region from lens to cornea, contain aqueous humor where [drug] is measured,
                           has volume of 300μL = small volume → drug is concentrated → effect
                       2. Posterior chamber – 57μL
              iii. Function
                       1. Provide nutrition for lens & cornea
                       2. Generate pressure → maintain intraocular psi shape of cornea
                               a. Normal condition – 15-18mmHg above Patm, > tissue (2-3mmHg) & CSF (7mmHg)
                               b. Glaucoma – 20-40mmHg → asymptomatic until vision is lost
                       3. Distribute drug → where [drug] is sampled
       g. Cornea – avascularized, thin, transparent elastic layer covering 1/6 eye surface → 1o tissue preventing drug from
          getting into eye = direct route into anterior chamber
                i. Avascularized → receive nutrient & antibody through diffusion from aqueous humor
               ii. Lack immune system → may develop herpes → lesion to cornea → Tx – cornea transplant
              iii. Tight junction – cell joint by tight junction → only allow lipophilic molecule < 5kDa to get in
              iv. Has 5 layers – corneal epithelium, Bowman’s MB, stroma, descemete’s MB, & endothelium




4. Bioavailability of topical ocular drug
      a. Precorneal factors influences ocular drug bioavailability/ uptake
               i. Mixing – due to reflex blinking, viscosity, miscibility, surface tension
              ii. Tear –0.7% protein (<< blood 7%)low buffereing capacity → allow drug to be buffered at any pH
                        1. Dilution – tear resident volume is 7.5μL → ↑ total volume of solution without ↑ in total drug amt →
                           ↓ [drug] → ↓ concentration gradient J = -D dC/dx
                                a. EX - drug droplet is 30μL, tear is 7.5uL → total volume is 37.5μL
                                b. Calculation EX – instill 30μL of 0.5% Timoptic → total volume – 30 + 10 = 40 μL →
                                   [drug] = (0.5% * 30μL) / 40μL = 0.375% → remained drug absorbed into systemic
                                   circulation
                        2. Drainage – into nasolacrimal duct → drug can be
                           delivered into systemic circulation through rich
                           vasculature of nasal cavity >< low volume = small drug
                           amount → must be a very potent drug
                                a. Eye tend to maintain tear volume constant at a
                                   turn-over rate of 16%/min (1μl/min) which ↓ as
                                   age ↑ & during sleep or local/ general
                                   anesthesia
                                b. Drug application/ ↑ pH or tonicity → disturb
                                   homeostatis → eye ↑ tear production = ↑ total
                                   volume → ↑ rate of drainage
                                c. The smaller the instilled volume, the lower
                                   turn-over rate, the longer drug remained in eye
                                   >< too small volume = not enough drug is
                                   delivered or drug is not soluble enough → most
                                   instilled volume = 25μL
                      3. pH = 7 on average >< varies from 7.30 to 7.5 throughout the day → influence drug absorption
                           depending when drug is applied
             iii. Osmolarity – 270 to 300 mOsm/L → drug at this osmolarity doesn’t not hurt
                      1. Hypotonic drug – give soothing effect >< cell swell → drug cant be absorbed well
                      2. Hypertonic drug – not comfortable → tearing → lost of drug due to drainage >< stabilize cell →
                           drug can be absorbed easily
                      3. Must choose a tonicity that is balanced between drug absorption & comfort
             iv. Protein binding – Drug + Protein → Drug-Protein = inactive drug – the more protein, the less drug
                  available for effect
              v. Metabolism – not well studied, may convert pro-drug into active drug. EX – xalatan must be metabolized
                  into active drug
             vi. Conjunctival loss – conjunctiva cover 80% eye surface with present of blood & lymphatic vessels → drug
                  can get into systemic circulation through large surface area
      b. Experiment
               i. 3 conditions – drug (A) exposed to cornea & conjunctiva, (B) only exposed to conjunctiva, (C) only
                  exposed to sclera (conjunctiva removed)
              ii. Measurement – in aqueous humor, cornea & ciliary body at different time
             iii. Conclusion –
                      1. Lipophilic drug – hydrocortisone → drug absorbed through cornea only
                      2. Hydrophilic drug – pilocarpine → some absorption into ciliary body → conjunctiva play some role
                           in drug absorption >< cornea is still major route of absorption
      c. Factors improve bioavailability
               i. ↓ solution drainage
              ii. ↓ tear turn over
             iii. ↓ drug metabolism
             iv. ↓ conjunctival absorption
              v. ↓ protein binding
             vi. EX – valycyclovir – metabolized into avacyclovir
                  (active form) by replacing NH2 group with OH (not
                  ionized at tear pH) → more drug can be absorbed +
                  valycyclovir are transported by protein transport into
                  cornea
            vii. EX – xalatan (synthetic prostaglandin) must be
                  metabolized into active form → must prevent
                  metabolism before prodrug entering cornea to ↑
                  amount of drug absorbed
5. Other ocular dosage form & their bioavailability – all dosage form has same elimination rate once dissolved
      a. Suspension – reside on cornea longer = depot effect (stick to
          conjunctiva → get release after drug in other area has been
          washed away) → work better than solution
               i. Middle line in graph – suspension = drug remained
                  in aqueous humor much longer after drug in solution
                  has been completely eliminated
      b. Ointment – use absorption base
               i. Advantages
                      1. ↑ viscosity → longer contact time (longest
                           among 3 different dosage form)
                      2. ↑ [oil-soluble drug] in oleaginous base→ ↑
                           concentration gradient. EX: fluorometholone
                      3. Water soluble drug (pilocarpine) → can be
                           made with surfactant >< not as much drug get in
              ii. Disadvantages
                      1. Mixing problem – ointment cant be mixed easily with tear → dependent on mechanical mixing to ↑
                           surface area for absorption
                      2. Uncomfortable – drug must partition from ointment to tears → drug might not want to get out of
                           ointment base
                      3. Rupture – ointment may soften cornea → ↑ rupture chance
      c. Inserts – contact lens form
               i. Controlling rate of release of drug → ↑ Pt compliance & ↓ systemic SE
               ii. Best for pilocarpine (has lots of side effect)
              iii. EX – ocusert for chronic open angle glaucoma – lens of flexible,, biocompatible ethylene/vinyl acetate
                   copolymer MB = hydrophobic → reistant osmotic uptake of water, z dilution of drug + core of pilocarpine
                   & alginic acid + annular ring
      d. Gel – bioadhesive system = solution that turn into gel when exposed to tear → adhesive bonding to mucin or
          epithelium → keep drug in place longer
                i. Type of gel
                       1. Form gel due to temperature stimulus – Poloxamer 407 (polysaccharide) → gel at body
                           temperature
                       2. Form gel due to pH stimulus – cellulose acetate phthalate (carbohydrate polymer) → gel at higher
                           pH → formulation must be made at pH 4.5 to prevent gelling → cant be used for eye due to low
                           buffering capacity + high pH is painful to eye
                       3. Form gel due to ions presence – Gelrite (low acetyle gellan gum = linear chain of polysaccharide
                           of glucose, rhamnose & glucuronic acid subunits) → gel in present of Na+, Ca2+, Mg2+ found in tear
      e. Subconjunctival route
                i. Iontophoresis – inject drug using electrodes (1 with drug on outside, 1 without inside) >< slow
               ii. Nano/microparticle matrix materials – implantation of polymer under conjunctiva → drug is released
                   overtime → good for chronic glaucoma
6. Route of systemic entry for topical ophthalmic drug
      a. Through conjunctiva & lymphatic drainage
      b. Through vascular system in back of eye after absorption (1-5%)
      c. Through nasal cavity vascular system → block this drainage with pressure → ↓ systemic absorption
      d. Case study – timolol systemic absorption




               i. Gel form – bottom line, has lowest systemic absorption (very low k1) since amount drug release is mostly
                  absorbed into eye → not as much drug get into nasal cavity
              ii. Suspension – middle line – almost as high systemic absorption as top line (solution) with longer duration in
                  plasma relative to solution
             iii. Solution – square dot – highest systemic side effect, but drug is also eliminated faster
7. Review questions
      a. How does volume of solution instilled affect percent of dose absorbed into eye? Inverse relationship
      b. Based on what is known of precorneal solutions dynamics,
               i. What would be the ideal instilled dose volume? Why? 30μL , < 30μL = not enough drug, > 30μL = too
                  high turn over rate
              ii. In multidrop therapy, would the order of drop instillation affect drug bioavailability? How far apart
                  should the drops be spaced? What would be a solution to the problem?
      c. How do polymers reduce the rate of solution drainage? Gel or contact lens
               i. What polymers can be used?
              ii. Would the chemical nature of the polymer affect the rate of solution drainage? Yes on lipiphilic vs.
                  hydrophilic drug
      d. How do solution pH and tonicity affect the percent of instilled dose of a weakly acidic drug that would be
          absorbed into the eye?
      e. Which of the five layers in the cornea is the rate-limiting barrier to the drug penetration? Epithelium
      f. How can the integrity of the corneal epithelium be disrupted? Oily substance can soften cornea
      g. How can corneal drug penetration be improved?
h. How would the size of the particles in an ophthalmic suspension affect ocular drug bioavailability?
i. Would the ocular pharmacokinetics of water-soluble drugs in an oleagenous ointment be the same as that of
   oil-soluble drugs? Please explain.
j. Would the drug release rate from an Ocusert be dependent on the physicochemical properties of the drug?
   Please explain.
k. Can precorneal drug residence be achieved using a soft-contact lens? Please explain.
l. How can systemic drug absorption following topical ocular drug administration be reduced?

				
DOCUMENT INFO